Skip to main content
Skip to footer
Home
About us
Our Business
Strategy and business model
Management
Board of Directors
Contact us
Pipeline
Our Science
Pipeline overview
Projects
Rugocrixan
Fosrugocrixan
Business Development
IP
Publications
Therapeutic areas
Myocardial infarction
Ovarian cancer
Investors
Presentations
Press Releases
Financial Reports
Financial Calendar
Events
The Share
Sustainability
Corporate Governance
Articles of Association
Annual General Meeting
Board Committee
Board
CEO and Management
Auditors
Certified Adviser
Home
About us
Our Business
Strategy and business model
Management
Board of Directors
Contact us
Pipeline
Our Science
Pipeline overview
Projects
Rugocrixan
Fosrugocrixan
Business Development
IP
Publications
Therapeutic areas
Myocardial infarction
Ovarian cancer
Investors
Presentations
Press Releases
Financial Reports
Financial Calendar
Events
The Share
Sustainability
Corporate Governance
Articles of Association
Annual General Meeting
Board Committee
Board
CEO and Management
Auditors
Certified Adviser
Start
>
News
News
Kancera reports inhibitory effects on pancreatic cancer in animal studies
Intellect Neurosciences and iNovacia Enter into a Research Service Agreement
Interim Report for Kancera AB (publ) Q2 2012
Kancera strengthens patent rights related to ROR antibody therapy
Kancera to present at the 2012 BIO International Convention
Professor Carl-Henrik Heldin strengthens the Board of Kancera
Interim Report for Kancera AB (publ) Q1 2012
Kancera´s ROR inhibitors are active against Fludarabine resistant leukemia
A new diagnostic tool increases the value of Kancera´s ROR technology
Data indicate broad utility of Kancera’s PFKFB3 inhibitors.
